HIV pre-exposure prophylaxis (PrEP) has proven efficacy in reducing the risk of HIV infection in men who have sex with men (MSM), but has not yet been commissioned in the UK. The aim of this study was to investigate perceived need and benefit (or experience of) PrEP among HIV-negative MSM attending sexual health clinics. HIV-negative MSM attending three sexual health centres in London, UK were opportunistically invited to complete a questionnaire. Data collected comprised demographic data and sexual and drug use behaviours as well as questions regarding perceptions of risk and need for PrEP. Logistic regression analysis was undertaken to identify variables predicting acceptability of, and intention to use, PrEP. In addition, data were gathered in respondents already taking PrEP. Eight hundred and thirty-nine questionnaires were analysed. The median age of respondents was 35 years (IQR 28-41, range 18-78), 650 (77%) were of white ethnicity and 649 (77%) had a university education. Four hundred and fifty-six (54%) reported at least one episode of condomless anal sex in the preceding three months, 437 (52%) reported recreational drug use in the preceding three months and 311 (37%) had been diagnosed with a sexually transmitted infection within the preceding six months. Four hundred and sixty-three (64%) of 726 strongly agreed with the statement 'I think I would benefit from PrEP'. Multivariate logistic regression analysis demonstrated that having receptive anal intercourse (RAI) without condoms, having an awareness of the risk of unprotected RAI and having belief in the effectiveness of PrEP were independent predictors for someone thinking they would benefit from taking PrEP. Eight percent of respondents (59/724) had already taken or were currently taking PrEP. The results suggest that individuals at risk are likely to perceive themselves as benefiting from PrEP. The majority perceived their risk of acquiring HIV and benefit from PrEP accurately. Overall they appeared to have little concern over the use of PrEP and generally positive attitudes. Further investigation is warranted to understand why those at risk do not perceive benefit from PrEP.
Introduction
HIV pre-exposure prophylaxis (PrEP) has demonstrated efficacy in reducing the risk of sexual acquisition of HIV infection. Based on placebo-controlled randomised trials, [1] [2] [3] the US Food and Drugs Administration approved the use of daily Truvada (tenofovir and emtricitabine) as PrEP in 2012. 4 In 2015 the UK PROUD study and French IPERGAY study both demonstrated a reduction of 86% in HIV incidence in men who have sex with men (MSM) taking daily or event-based Truvada, respectively. 5, 6 Following these results the World Health Organisation issued a strong recommendation that PrEP be added to the HIV risk reduction package for MSM.
An estimated 103,700 individuals were living with HIV in the UK at the end of 2014. 7 Gay, bisexual and other MSM are the population most at risk of acquiring HIV. 7 Despite an increase in HIV testing and a trend towards earlier initiation of antiretroviral therapy (ART), 8, 9 there had been no decrease in the numbers of new diagnoses reported each year in MSM for the past decade (numbering 3360 new diagnoses in 2014). 7 However, recent data have shown a reduction in new diagnoses of HIV in MSM in 2016, 10 thought likely to be as a result of the interplay between frequent testing, prompt initiation of ART and the use of PrEP. Although scale-up of HIV testing and promotion of condom use remain important risk reduction measures, PrEP offers an additional approach for those whose condom use is inconsistent with partners whose HIV and treatment status is unknown.
Modelling suggests that introducing PrEP in the UK would be cost effective and cost saving if targeted to those most at risk of acquiring HIV 11 in the context of provision to an appropriate population. 12 Evidence thus far has demonstrated that PrEP is most likely to be used by those who engage in highrisk behaviour. 13, 14 At the time this study started, the commissioning process for PrEP in England and Wales was under review. The purpose of this study was to gain understanding of the perceived risk of acquiring HIV, need for PrEP and the likelihood of uptake amongst HIVnegative MSM attending sexual health clinics in London to inform PrEP delivery.
Methods
Eligible participants were HIV-negative MSM aged over 18 attending three sexual health centres in London. These clinics were all participating in the PROUD study and the questionnaire was implemented after the results were reported. At all sites the questionnaire was offered opportunistically when eligible participants were identified during clinic visits or took a questionnaire from the waiting room (see online Supplemental Material). An accompanying patient information leaflet was provided containing information regarding PrEP and the intended aims of the study.
The The questionnaire was piloted among 20 intended respondents to check for understanding and acceptability of a broad range of questions: demographic, sexual history, drug use, history of sexually transmitted infections (STIs) and prior use of HIV post-exposure prophylaxis (PEP). Participants were also asked to respond to a 10-point Likert scale for HIV risk perception and perceived need/likely benefit of PrEP. For the purposes of analysis 8 was considered strong agreement. Participants were asked about their preferred regimen, whether they had already taken it and, if so, how they had sourced it. Those who had previously used PrEP were asked if their sexual behaviour had changed as a result.
The intended sample size was 1000. Bivariate and multivariate logistic regression analyses were undertaken to identify factors associated with perceived need/ likely benefit of PrEP and intentions of use. For the purposes of this analysis the mean (which was the same as the median) response on Likert scale was used to create a dichotomous category. Data were collated in Microsoft Excel and analysed in IBM SPSS (v24).
Results

(1) Demographic characteristics of respondents
The total number of questionnaires received was 859. Twenty-six were completed by heterosexuals; six of these reported receptive anal intercourse (RAI) and their questionnaires were included in the analysis, leaving 839 questionnaires in the dataset. Respondents came from clinics across London; 150 from the Homerton, 71 from St Marys and 618 from Chelsea and Westminster, with over half (550) from one Chelsea and Westminster clinic based in Soho (Dean Street).
Demographic and other characteristics of respondents are presented in Table 1 . The median age of respondents was 35 years (IQR 28-41, range 18-78). The majority were white, well educated and self-identified as homosexual. There were 82 different nationalities represented and half the respondents were born outside the UK.
(2) Risk behaviours and perceived risk of HIV Regarding sexual behaviour in the preceding month, 739 (88%) of respondents reported anal intercourse (AI), 456 (54%) with at least one condomless partner in the preceding three months and 232 (28%) with two or more condomless partners in the preceding three months. The median number of sexual partners with and without a condom according to position in the preceding three months is demonstrated in Table 2 .
Regarding drug use in the preceding three months, 437 (52%) reported use of any drug. The most commonly used drugs were mephedrone (30%), poppers (23%) and 'G' (GBL/GHB) (22%). Nine percent had used crystal methamphetamine and 26 (3%) reported injecting (mephedrone, G or crystal methamphetamine). No respondents reported sharing of injecting drug equipment. Two hundred and thirty (27%) reported drug use specifically to facilitate sex (socalled chemsex) within the last month. Of this group, 74 (32%) reported sober sex without drug use within the past week, but 33 (14%) last experienced sober sex more than three months ago. Regarding STIs: 49 (6%) did not answer this question; 311 (37%) had been diagnosed with an STI within the preceding six months. Pharyngeal and/or penile infection with chlamydia or gonorrhoea were the most common. Rectal infection was reported by 119 (14%) and syphilis by 52 (6%).
Just over half of respondents had undergone an HIV test within the preceding three months. Only 70 (9%) had not had a test in the preceding 12 months, although 63 (8%) did not answer this question. Use of PEP at any time was reported by 282 (34%) on a mean of 1.2 occasions (range 1-9) in the last year.
Respondents were asked to complete a table regarding their perceived risk of acquiring HIV in a number of different sexual scenarios, rating the risk level from 1 (low) to 10 (high). Table 3 shows the mean response to these questions.
(3) Knowledge of PrEP
The vast majority, 684 (82%), had heard of PrEP prior to completing the questionnaire. The perceived effectiveness of PrEP was high, with 608 (72%) rating this 8/10 on the Likert scale (where 1 ¼ not effective and 10 ¼ very effective). Only 11 (1%) rated effectiveness as 3/10. Respondents were also asked about their perceived effectiveness of PEP (scale: completely, very, somewhat, not really, not at all). Only 246 participants answered this question and the majority 169 (69%) rated it as very effective, with 37 (15%) and 36 (15%) rating it completely or somewhat effective, respectively.
(4) Perceived benefit from PrEP
We asked respondents to indicate their agreement with the statement 'I think I would benefit from PrEP'. Of 726 people responding to this question, 463 (64%) rated their agreement 8/10 (where 1 ¼ strongly disagree and 10 ¼ strongly agree). Of those strongly agreeing with this statement, 82 (18%) had not reported condomless sex in the last three months, although 47 (10%) reported other risk factors for HIV acquisition (PEP use, chemsex use and a rectal STI in the preceding six months), leaving only 35 (8%) who reported no risk but perceived a benefit from PrEP. Of the 98 (13%) who rated their agreement 3, 15 (15%) reported AI without a condom with at least two people in the preceding three months. However, four of these 15 (27%) had unprotected sex only with HIV-positive people on ART thus rationalising this view.
To better understand the factors associated with agreeing with the statement 'I think I would benefit from PrEP' the mean response of 7 was used to create a dichotomous category of agreeing or disagreeing with this statement (7 as agreement or <7 as disagreement). Univariate and multivariate logistic regression analysis were then undertaken to identify variables independently predicting the likelihood of perceived benefit from PrEP. In the univariate regression analysis, having condomless insertive or RAI (UPIAI or unprotected receptive anal intercourse [UPRAI], respectively) in the preceding three months, use of recreational drugs, chemsex use, having an STI in the preceding six months, having used PEP before, having belief in the effectiveness of PrEP and being willing to pay for PrEP were all significantly associated with likelihood of perceived benefit of PrEP. As shown in Table 4 , in the multivariable regression analysis reporting UPRAI, having an awareness of the risk of UPRAI, and higher perceived effectiveness of PrEP were independent predictors for someone thinking they would benefit from PrEP. Having taken PEP Table 2 . Number of reported partners in the last month, median, IQR and range. before and being willing to pay for PrEP were also independent predictors of perceived benefit from PrEP.
Respondents were asked if they would have concerns about taking PrEP. Of 638 who did not have previous experience of PrEP and who answered this question, 253 (40%) scored 3 on a Likert scale of 1=no concerns, to 10=high level of concern, 241 (38%) marked 4-7 and 144 (22%) marked 8-10 implying they would have concerns. The proportions remained the same when PrEP users were included. However, when asked specifically what those concerns would be, only 12 people (of all respondents) cited reasons: the majority (eight) citing side effects. Respondents were then asked if having to make regular clinic visits would act as a disincentive to being on PrEP, and 104 (15%) of 687 answering this question scored 8/10 on a Likert scale (where 10=high level of concern).
Of 724 who answered the willingness to pay for PrEP questions (PrEP users and non-users included), 236 (33%) strongly disagreed scoring 3 on a Likert scale, 308 (43%) were neutral scoring 4-7 and a quarter; 180 (25%) strongly agreed (180/724, 8/10). Respondents when then asked whether they agreed, disagreed or were not sure about six statements on provision of and payment for PrEP. The vast majority 640 (85%) of 754 agreed with the statement 'I think PrEP should be available for free in sexual health centres to MSM'. There was ambivalence about the statement 'I think there should be a prescription charge for PrEP in most cases' with 227 (31%) of 743 agreeing; 323 (43%) disagreeing and 193 (26%) who were not sure.
When asked about the preferred regimen for PrEP, 353 (54%) of 653 preferred a daily regimen and 282 (43%) preferred to take it before and after sex.
(5) Previous and current use of PrEP
Of 724 respondents 59 (8%) had already taken or were currently taking PrEP, of whom 23 (39%) had taken it for less than a month and 14 (23%) for more than a year. The majority 50 (80%) were taking it daily.
Nearly a quarter (14) of those who had taken PrEP had paid for their medication, either privately (eight), online (four) or abroad (two), reporting costs of £150-£400 per month. Nearly half (26) had obtained PEP to use as PrEP and the remainder were on a trial (14) or used a friend or partner's medication (five).
Discussion
This questionnaire study of sexual health clinic attendees demonstrates good awareness of PrEP amongst a group of MSM generally reporting high-risk sexual and drug-taking behaviour.
Respondents were homogenous (a highly-educated, predominantly white, urban, British/Europeanborn group).
There are high levels of self-reported STIs in the preceding six months compared to the number of infections diagnosed in MSM attending GUM clinics in the UK. 15, 16 Use of PEP in the past year was significantly higher than national surveillance data, with nearly 20% using it more than once. These risk behaviours are similar to what was demonstrated in the baseline characteristics of PROUD participants. 17 Respondents correctly perceived that RAI is riskier than insertive AI, and that antiretrovirals reduce this risk. Anal sex with an HIV-positive partner on treatment was ranked higher risk than anal sex with a selfreported HIV-negative partner for both insertive and receptive positions. In retrospect this question did not state clearly self-reported HIV status, and thus it is difficult to draw firm conclusions about this fact.
The regression analyses demonstrate that those who participate in high-risk behaviour, such as recreational drug use, condomless anal sex and PEP use, have an awareness of the behaviours that increase risk and believe in the effectiveness of PrEP. Thus, this group feel they would benefit most from PrEP. The small Overall there appear to be few concerns over the use of PrEP and generally positive attitudes towards its use. The preferences for regimen (54% daily versus 43% on demand) reflect patterns of use in the French national programme, and this emphasises the importance of offering choice. However, it is interesting to note that there is disparity between respondents to this survey who are already using PrEP and choosing daily dosing (80%) versus survey respondents who said they would prefer daily dosing (54%). It is difficult to know why this may be the case, although current users are a much smaller group in this sample.
There are several limitations to this study, in particular the lack of a random sampling framework. As questionnaires were offered opportunistically and also left for respondents in waiting rooms we do not have data on a response rate. Furthermore, we chose to conduct the study in clinics that were participating in PROUD, where awareness of PrEP is likely to be higher amongst staff and attendees. As a result the sample is highly selective and we cannot extrapolate to the general population of MSM. However, approximately one in five MSM attend sexual health clinics each year and over half will attend one of the participating PROUD clinics. The four clinics that took part in this study enrolled a significant proportion of the PROUD participants and diagnosed more than one in five of HIV infections in MSM in England in 2015. These clinic populations would be the first to implement a national PrEP programme if it is commissioned.
During the course of this study, Truvada as oncedaily PrEP was approved by the European Medicines Agency. Whilst the provision of PrEP remains a contested issue in the UK, it is clear that the respondents of this survey feel that PrEP should be widely available. This survey provides further information which may be useful for planning PrEP implementation; particularly that self-identification of risk, which has been shown to be a marker of true risk in other studies, may be a valid strategy for PrEP provision. The results add to the clamour of voices calling for provision of PrEP to populations at risk via the UK's established network of sexual health clinics.
Key points
1. PrEP has proven real-world effectiveness in clinical trials and has now been approved by the EMA in the form of Truvada once daily.
2. This survey demonstrates good awareness of PrEP and generally positive attitudes amongst a group of high-risk MSM 3. In this study MSM who exhibit high-risk behaviour accurately perceive their risk and need for PrEP.
